FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie
The FDA's acceptance of the supplemental application for SKYRIZI indicates a potential expansion of AbbVie's market presence in the IL-23 inhibitor segment. This could lead to intensified competition, particularly against established products like Tremfya and Benlysta.
Company
AbbVie
Asset
SKYRIZI
Indication
Immunology / IL-23
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's acceptance of the supplemental application for SKYRIZI indicates a potential expansion of AbbVie's market presence in the IL-23 inhibitor segment. This could lead to intensified competition, particularly against established products like Tremfya and Benlysta.
Why it matters
The FDA's acceptance of the supplemental application for SKYRIZI indicates a potential expansion of AbbVie's market presence in the IL-23 inhibitor segment. This could lead to intensified competition, particularly against established products like Tremfya and Benlysta.
What changed
Regulatory Approval
Analysis
The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.
The FDA's acceptance of the supplemental application for SKYRIZI indicates a potential expansion of AbbVie's market presence in the IL-23 inhibitor segment. This could lead to intensified competition, particularly against established products like Tremfya and Benlysta.
Monitor the timeline for the FDA's final decision and any subsequent market reactions from competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.